This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Gourdon G, Meola G. Myotonic dystrophies: State of the art of new therapeutic developments for the CNS. Front Cell Neurosci. 2017; 11: 101.GourdonGMeolaGMyotonic dystrophies: State of the art of new therapeutic developments for the CNSFront Cell Neurosci20171110110.3389/fncel.2017.00101539740928473756Search in Google Scholar
Finsterer J, Stöllberger C. Myotonic dystrophy-1 complicated by factor-v (Leyden) mutation. Case Rep Med. 2015; 2015: 271639.FinstererJStöllbergerCMyotonic dystrophy-1 complicated by factor-v (Leyden) mutationCase Rep Med2015201527163910.1155/2015/271639439703825918532Search in Google Scholar
Mohamed S, Pruna L, Kaminsky P. Increasing risk of tumors in myotonic dystrophy type 1. Presse Med. 2013; 42(9): e281-e284.MohamedSPrunaLKaminskyPIncreasing risk of tumors in myotonic dystrophy type 1Presse Med2013429e281e28410.1016/j.lpm.2013.01.05223477718Search in Google Scholar
Dalvin LA, Shields CL, Pulido JS, Sioufi K, Cohen V, Shields JA. Uveal melanoma associated with myotonic dystrophy: A report of 6 cases. JAMA Ophthalmol. 2018; 136(5): 543-547.DalvinLAShieldsCLPulidoJSSioufiKCohenVShieldsJAUveal melanoma associated with myotonic dystrophy: A report of 6 casesJAMA Ophthalmol2018136554354710.1001/jamaophthalmol.2018.0554587691429596556Search in Google Scholar
Marcoval J, Olive M, Bonfill-Orti M, Martinez-Molina L, Talavera-Belmonte A. Cutaneous neoplasms in myotonic dystrophy type 1. Dermatology. 2016; 232(6): 700-703.MarcovalJOliveMBonfill-OrtiMMartinez-MolinaLTalavera-BelmonteACutaneous neoplasms in myotonic dystrophy type 1Dermatology2016232670070310.1159/00045607428249295Search in Google Scholar
Campione E, Botta A, Di Prete M, Rastelli E, Gibellini M, Petrucci A, et al. Cutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasis. Neuromuscul Disord. 2017; 27(2): 163-169.CampioneEBottaADiPrete MRastelliEGibelliniMPetrucciACutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasisNeuromuscul Disord201727216316910.1016/j.nmd.2016.11.00428065683Search in Google Scholar
Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM. Increased cancer risks in myotonic dystrophy. Mayo Clin Proc. 2012; 87(2): 130-135.WinAKPeratturPGPulidoJSPulidoCMLindorNMIncreased cancer risks in myotonic dystrophyMayo Clin Proc201287213013510.1016/j.mayocp.2011.09.005349833222237010Search in Google Scholar
Finsterer J. Myotonic dystrophy type 1 and 2. In: Burgess VN, Editor. Progress in Muscular Dystrophy Research. Hauppauge, NY, USA: Nova Science Publishers. 2005; 149-180. (ISBN: 1-59454-375-5.)FinstererJMyotonic dystrophy type 1 and 2BurgessVNProgress in Muscular Dystrophy ResearchHauppauge, NY, USANova Science Publishers2005149180(ISBN: 1-59454-375-5.)Search in Google Scholar
Addeo A, Bini R, Viora T, Bonaccorsi L, Leli R. Von Hippel-Lindau and myotonic dystrophy of Steinert along with pancreatic neuroendocrine tumor and renal clear cell carcinomal neoplasm: Case report and review of the literature. Int J Surg Case Rep. 2013; 4(8): 648-650.AddeoABiniRVioraTBonaccorsiLLeliRVon Hippel-Lindau and myotonic dystrophy of Steinert along with pancreatic neuroendocrine tumor and renal clear cell carcinomal neoplasm: Case report and review of the literatureInt J Surg Case Rep20134864865010.1016/j.ijscr.2013.03.004371091423774333Search in Google Scholar
Mavridou P, Dimitriou V, Margaritis A, Manataki A. Anesthesia for laparoscopic surgery in a patient with myotonic dystrophy (Steinert’s disease): Beneficial use of sugammadex, but incorrect use of pethidine: A case report. Acta Anaesthesiol Belg 2011; 62(2): 101-104.MavridouPDimitriouVMargaritisAManatakiAAnesthesia for laparoscopic surgery in a patient with myotonic dystrophy (Steinert’s disease): Beneficial use of sugammadex, but incorrect use of pethidine: A case reportActa Anaesthesiol Belg2011622101104Search in Google Scholar
